Novartis to buy kidney disease drugmaker in $3B deal; how data integrity issues roiled a high-profile biotech

Taking stock of the drug industry, from the lab to the medicine chest

June 12, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jeff Spicer/PA Wire via AP STAT+ | Francis deSouza's tenure at Illumina is a lesson in how not to handle CEO succession The roots of the resignation of CEO Francis deSouza lay in the original handoff from his predecessor, Jay Flatley. By Matthew Herper STAT+ | The inside story of how data integrity issues roiled a biotech seen as 'Moderna 2.0' At Laronde, a recent episode highlighted how easy it can be to get carried away with the promise of new therapies, despite signs of trouble. By Allison DeAngelis and Ryan Cross — The Boston Globe STAT+ | Novartis to buy Chinook Therapeutics, developer of kidney disease therapies, in $3.2 billion deal Novartis will pick up two drugs in late-stage trials aimed at a chronic kidney disease. By Andrew Joseph Karen Pennar/STAT Ro pauses advertising of weight loss drug Wegovy amid shortages Ro's ads offering Wegovy to the masses had waded into a regulatory gray area of direct-to-consumer drug advertising. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser